307 related articles for article (PubMed ID: 27529345)
1. Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.
Dietz S; Schirmer U; Mercé C; von Bubnoff N; Dahl E; Meister M; Muley T; Thomas M; Sültmann H
PLoS One; 2016; 11(8):e0161012. PubMed ID: 27529345
[TBL] [Abstract][Full Text] [Related]
2. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
[TBL] [Abstract][Full Text] [Related]
3. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C
Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523
[TBL] [Abstract][Full Text] [Related]
4. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
[TBL] [Abstract][Full Text] [Related]
5. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
7. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
[TBL] [Abstract][Full Text] [Related]
8. Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.
Vanni I; Coco S; Truini A; Rusmini M; Dal Bello MG; Alama A; Banelli B; Mora M; Rijavec E; Barletta G; Genova C; Biello F; Maggioni C; Grossi F
Int J Mol Sci; 2015 Dec; 16(12):28765-82. PubMed ID: 26633390
[TBL] [Abstract][Full Text] [Related]
9. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
[TBL] [Abstract][Full Text] [Related]
10. Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors.
Saber A; Hiltermann TJN; Kok K; Terpstra MM; de Lange K; Timens W; Groen HJM; van den Berg A
Carcinogenesis; 2017 Feb; 38(2):144-151. PubMed ID: 27993895
[TBL] [Abstract][Full Text] [Related]
11. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
12. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
[TBL] [Abstract][Full Text] [Related]
13. Read Count Patterns and Detection of Cancerous Copy Number Alterations in Plasma Cell-Free DNA Whole Exome Sequencing Data for Advanced Non-Small Cell Lung Cancer.
Jang H; Choi CM; Lee SH; Lee S; Jeong MK
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361723
[TBL] [Abstract][Full Text] [Related]
14. Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis.
Koba H; Kimura H; Yoneda T; Sone T; Ohkura N; Hara J; Hosomichi K; Tajima A; Kasahara K
Sci Rep; 2021 Apr; 11(1):8398. PubMed ID: 33863951
[TBL] [Abstract][Full Text] [Related]
15. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
Goto K; Ichinose Y; Ohe Y; Yamamoto N; Negoro S; Nishio K; Itoh Y; Jiang H; Duffield E; McCormack R; Saijo N; Mok T; Fukuoka M
J Thorac Oncol; 2012 Jan; 7(1):115-21. PubMed ID: 21900837
[TBL] [Abstract][Full Text] [Related]
17. Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer.
O'Brien TD; Jia P; Xia J; Saxena U; Jin H; Vuong H; Kim P; Wang Q; Aryee MJ; Mino-Kenudson M; Engelman JA; Le LP; Iafrate AJ; Heist RS; Pao W; Zhao Z
Methods; 2015 Jul; 83():118-27. PubMed ID: 25913717
[TBL] [Abstract][Full Text] [Related]
18. Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Butler TM; Johnson-Camacho K; Peto M; Wang NJ; Macey TA; Korkola JE; Koppie TM; Corless CL; Gray JW; Spellman PT
PLoS One; 2015; 10(8):e0136407. PubMed ID: 26317216
[TBL] [Abstract][Full Text] [Related]
19. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
[TBL] [Abstract][Full Text] [Related]
20. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
